Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.53 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097272 | 0.90 | EHMT2 (0.62) | KDM4EALDH1A1RXFP1EHMT2EHMT1 | |
| SCHEMBL5087597 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1RXFP1OPRK1OPRM1 | |
| SCHEMBL5089736 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1RXFP1EHMT2EHMT1 | |
| SCHEMBL5038741 | 0.80 | NPC1 (0.67) | KDM4EALDH1A1RXFP1EHMT2OPRK1 | |
| SCHEMBL5087662 | 0.78 | NPC1 (0.51) | KDM4EALDH1A1RXFP1OPRK1POLB | |
| SCHEMBL5096483 | 0.77 | EHMT2 (0.60) | KDM4EALDH1A1RXFP1EHMT2EHMT1 | |
| SCHEMBL5089715 | 0.76 | STING1 (0.56) | KDM4EALDH1A1RXFP1EHMT2OPRK1 | |
| SCHEMBL26606479 | 0.75 | KDM4E (0.58) | KDM4EALDH1A1RXFP1EHMT2OPRK1 | |
| SCHEMBL5090621 | 0.73 | ALDH1A1 (0.59) | KDM4EALDH1A1RXFP1OPRK1OPRM1 | |
| SCHEMBL11710636 | 0.73 | OPRK1 (0.64) | KDM4EALDH1A1RXFP1EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338956-B2 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-04 | — | — | US | disclosed |
| EP-1534275-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014369-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388341-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | EDNRA, LIPG, CYP11B1 | KDM4E 861/4885ALDH1A1 320/4885RXFP1 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.